Merck & Co., Inc. (NYSE:MRK) Rating Increased to Buy at Wall Street Zen

Merck & Co., Inc. ( NYSE:MRK - Get Free Report ) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday. A number of other equities analysts have also weighed in on MRK. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a research report on Monday, April 6th. Zacks Research raised Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. UBS Group increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Monday, April 13th. Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an "overweight" rating and a $140.00 price target for the company. Finally, Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating for the company in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $128.18. Shares of NYSE:MRK opened at $121.05 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The stock's 50 day moving average is $116.55 and its 200-day moving average is $112.39. The firm has a market capitalization of $298.96 billion, a price-to-earnings ratio of 34.10, a PEG ratio of 2.70 and a beta of 0.21. Merck & Co., Inc. ( NYSE:MRK - Get Free Report ) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the firm earned $2.22 earnings per share. Merck & Co., Inc.'s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year. A number of institutional investors have recently bought and sold shares of the business. Chesapeake Wealth Management grew its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock valued at $1,552,000 after purchasing an additional 87 shares during the period. South Plains Financial Inc. grew its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company's stock valued at $1,635,000 after purchasing an additional 89 shares during the period. Syverson Strege & Co grew its stake in Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company's stock valued at $436,000 after purchasing an additional 90 shares during the period. Nations Financial Group Inc. IA ADV grew its stake in Merck & Co., Inc. by 0.4% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company's stock valued at $2,819,000 after purchasing an additional 91 shares during the period. Finally, Westside Investment Management Inc. grew its stake in Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock valued at $331,000 after purchasing an additional 93 shares during the period. Institutional investors own 76.07% of the company's stock. Here are the key news stories impacting Merck & Co., Inc. this week: Positive Sentiment: Merck reached a settlement of more than $50 million to resolve over 200 Gardasil-related lawsuits, removing a significant legal overhang and helping investors refocus on the company’s core business and pipeline. Positive Sentiment: Merck recently broke above both its 20-day and 50-day moving averages, a technical signal that traders often view as a sign of improving short-term momentum. Positive Sentiment: Merck’s oncology franchise continues to draw attention after ASCO 2026 updates highlighted Keytruda’s strength in solid tumors and other pipeline assets aimed at offsetting future exclusivity pressure. Positive Sentiment: Merck’s collaboration with Moderna on a personalized mRNA cancer vaccine also got a boost from positive long-term data disclosed by Moderna, reinforcing investor interest in the partnership. Neutral Sentiment: Merck’s conference appearance and oncology strategy update likely kept investor focus on the pipeline, but the items available do not indicate a major new catalyst beyond ongoing progress. Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health. Founded in the late 19th century as the U.S.